{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Becker AMD"],"funding":["European Research Council","Dutch Research Council (NWO)"],"pagination":["101048"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12454896"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(9)"],"pubmed_abstract":["Dendritic cells (DCs) are professional antigen-presenting cells endowed with the capacity to initiate strong antitumor immune responses. This function is critical for effective DC-based immunotherapies but is often hampered by tumor-derived immunosuppressive factors, as is observed for CD14<sup>+</sup>CD163<sup>+</sup> tumor-induced DC3s (ti-DC3s). ti-DC3s are increased in cancer patients where they display an immunosuppressive phenotype, accompanied by weak antigen-specific CD8 T cell-activating capacities. While tumor-derived interleukin-6, macrophage colony-stimulating factor, and prostaglandin E2 have been identified as factors inducing the transition from DC2s to ti-DC3s, a comprehensive unbiased profiling of the resulting changes in secretome and proteome has not been reported. Here,"],"journal":["Molecular & cellular proteomics : MCP"],"pubmed_title":["Proteome and Secretome Profiling of the Melanoma-Induced Transition Toward Immune Incompetent Dendritic Cells Reveals Enhanced IDO1, Cathepsin, and Legumain Activity."],"pmcid":["PMC12454896"],"funding_grant_id":["024.002.009","679921"],"pubmed_authors":["Ignacio BJ","Ziegler AR","Verdoes M","Ramos-Tomillero I","Bonger KM","de Vries IJM","van Dalen FJ","Edgington-Mitchell LE","Becker AMD","Vermeulen M","Dijkstra JJ"],"additional_accession":[]},"is_claimable":false,"name":"Proteome and Secretome Profiling of the Melanoma-Induced Transition Toward Immune Incompetent Dendritic Cells Reveals Enhanced IDO1, Cathepsin, and Legumain Activity.","description":"Dendritic cells (DCs) are professional antigen-presenting cells endowed with the capacity to initiate strong antitumor immune responses. This function is critical for effective DC-based immunotherapies but is often hampered by tumor-derived immunosuppressive factors, as is observed for CD14<sup>+</sup>CD163<sup>+</sup> tumor-induced DC3s (ti-DC3s). ti-DC3s are increased in cancer patients where they display an immunosuppressive phenotype, accompanied by weak antigen-specific CD8 T cell-activating capacities. While tumor-derived interleukin-6, macrophage colony-stimulating factor, and prostaglandin E2 have been identified as factors inducing the transition from DC2s to ti-DC3s, a comprehensive unbiased profiling of the resulting changes in secretome and proteome has not been reported. Here,","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-06-03T19:54:13.909Z","creation":"2026-05-01T03:10:47.16Z"},"accession":"S-EPMC12454896","cross_references":{"pubmed":["40789452"],"doi":["10.1016/j.mcpro.2025.101048"]}}